Cargando…
Making the case: developing innovative adherence solutions for the treatment of tuberculosis
Autores principales: | Verma, Malvika, Furin, Jennifer, Langer, Robert, Traverso, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361324/ https://www.ncbi.nlm.nih.gov/pubmed/30815283 http://dx.doi.org/10.1136/bmjgh-2018-001323 |
Ejemplares similares
-
Tuberculosis innovations mean little if they cannot save lives
por: Pai, Madhukar, et al.
Publicado: (2017) -
Quality of drug-resistant tuberculosis care: Gaps and solutions
por: Udwadia, Zarir, et al.
Publicado: (2019) -
Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant
Tuberculosis with inhA Mutations
por: Wasserman, Sean, et al.
Publicado: (2020) -
The Reductionist Conundrum of an “Updated” Definition of Extensively Drug-Resistant Tuberculosis
por: Mitnick, Carole D., et al.
Publicado: (2021) -
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
por: Baryakova, Tsvetelina H., et al.
Publicado: (2023)